JGHF Okuda State-of-the-Art Lecture
Selection of Lecturer
- The APDW Federation nominates three (3) potential lecturers and appropriate topics.
- The potential nominees should come from more than one country within Asia Pacific region.
- The JGH Foundation will make the final decision on the selection of the lecturer in the year preceding the lecture.
- The APDW Federation will advise the APDW Local Organising Committee who will notify the selected lecturer.
The funding package is to assist in covering the following expenses:
- Return airfares economy for national sector and business class for international sector (or two economy class airfares for the full trip to equivalent cost) between home city and the venue for the APDW meeting.
- Accommodation for the duration of APDW.
- Honorarium of US$2,000 for submission of manuscript at the time of the meeting for publication in the Journal of Gastroenterology and Hepatology (JGH).
- All travel and accommodation arrangements will be made by the APDW organisers.
- The selected Lecturer must ensure that both a manuscript and all relevant receipts are provided to the APDW organisers to receive reimbursement and payment.
The JGHF Okuda State of the Art Lecturer is required to submit a manuscript at the time of the meeting that will cover the content of his/her lecture. The manuscript should be structured as a review article between 3,000-5,000 words and between 3-8 tables and figures. It is expected that this will be a detailed and learned exposé of the topic concerned, and will also emphasise practical points for clinicians and investigators. For information on JGH style guidelines please see the Wiley-Blackwell House Style Guide
Past Award Recipients
|2022||Ji-dong Jia||Beijing||Novel Diagnosis and Therapy for Autoimmune Liver Diseases|
|2021||Kazuichi Okazaki||Osaka||Current Perspectives on IgG4-Related Disease in Hepato-Gastroenterology|
|2019||Tooru Shimosegawa||Sendai||Clinical features and diagnosis of early-stage pancreatic cancer|
|2018||Henry Chan||Hong Kong||Challenges of Hepatitis B in the Era of Antiviral Therapy|
|2017||Ching Lung Lai||Hong Kong||Chronic Hepatitis B: HBsAg seroclearance, cccDNA and Treatment under Trial|
|2016||John Windsor||Auckland||Novel strategies for treating severe acute pancreatitis|
|2015||Edward Gane||Auckland||Advances in HCV Therapy- Towards a Global HCV Elimination|
|2014||Stephen Locarnini||Melbourne||New Therapeutic Targets Against Hepatitis B Virus: The Need for Molecular and Immune Based Treatments|
|2013||Fu-sheng Wang||Beijing||Immune disorders lead to liver damage and influence antiviral efficacy in patients with chronic HBV infection|
|2012||Jia-Horng Kao||Taipei||Risk stratification for HBV-related HCC, Jia Horng Kao, Taipei|
|2011||Mashashi Mizokami||Chiba||Optimising Treatment for Chronic Hepatitis C - incorporating molecular medicine into clinical practice|
|2010||Anna Suk-Fong Lok||Michigan||Does antiviral therapy for hep B & C prevent HCC?|
|2009||Ding-Shinn Chen||Taipei||Towards Elimination and Eradication of Hepatitis B|
|2008||Masashi Mizokami||Nagoya||Management of hepatocellular carcinoma; From surveillance to molecular targeted therapy.|
|2007||No award made|
|2006||Malcolm Alison||London||Stem Cell Therapy in Liver Diseases|
|2005||Sung-Gyu Lee||Seoul||Asian Contribution to living donor liver transplantation|
|2004||Daiming Fan||Xian||A bird’s-eye view on gastric cancer research of the past 25 years|
|2003||Shiu-Kum Lam||Hong Kong||The role of cyclo-oxygenase (COX) in GI Diseases|
|2002||Yun-Fan Liaw||Taipei||Hepatitis flares and HBeAg seroconversion: Implications in anti-HBV|